When Every 
Moment Counts

X

Ms. Dikla Czaczkes Akselbrad serves as the Chief Executive Officer of PolyPid after serving as the company’s EVP and CFO since 2017, leading the company’s initial public offering on the Nasdaq Global Market in June 2020. Dikla brings more than 20 years of experience leading life sciences companies through critical international strategic, financial and business transitions, including raising over $350 million in various forms in her prior executive roles. Before joining PolyPid in 2014, Dikla served as CFO of Compugen Ltd. (NASDAQ & TASE: CGEN) after serving as CFO of Packet Technologies Ltd., and an audit manager at Ernst & Young Israel. She received a B.A. in accounting and economics and an MBA from Tel-Aviv University, and is a certified public accountant in Israel.

X

Ms. Hazan brings over 25 years of expertise in the pharmaceutical industry, specializing in regulatory affairs and drug development. With a strong background in Research & Development, Clinical, and Regulatory Affairs, she has led successful regulatory meetings and submissions to the FDA, EMA, Health Canada, and other global health authorities. Ms. Hazan has a proven track record in overseeing clinical development and managing clinical studies. Prior to her current role, she held senior regulatory affairs positions at Teva Pharmaceuticals Ltd. She holds an M.Sc. in Physiology and Pharmacology from the Faculty of Medicine at Tel Aviv University and an Executive MBA from Bar Ilan University.

X

Ori has over 15 years of international experience in the pharmaceuticals industry with experience ranging from corporate strategy and business development to marketing and market access. Prior to joining Polypid Ori spent 10 years at Teva Pharmaceuticals with his last role being Senior Director of Oncology Marketing where he led the launch of several oncology products. Earlier in his career Ori served as the Head of Market Access for Teva in Canada and as Chief of Staff to the CEO of Teva’s global generics business. Ori started his career as a biotech engineer both in Israel and the US.

Ori holds a B.Sc. degree in Biotechnology Engineering from the Ben-Gurion University and an MBA from Duke University’s Fuqua School of Business.

X

Dr. Hagai is a seasoned Life Sciences executive with 20 years of successful track record in corporate Marketing & Business Development positions at various big pharma companies. Before joining Polypid, he served two years as VP Business development for Biotech Company at Aurum Ventures, the technology investment arm of Morris Kahn. Previously he held senior global positions at Teva Pharmaceuticals including Director of Global Strategic Marketing for innovative drugs in Multiple Sclerosis and Global head of Women’s Health Portfolio for EMIA-APAC region. Dr. Hagai holds a Pharm.D, is a Doctor in Clinical Biology and also holds a Master in Marketing (Paris V University).

X

Mr. Missulawin has over 15 years’ experience in financial operations in Hi-Tech and biotechnology companies. Before joining Polypid, Mr. Missulawin was an audit Senior at Ernst & Young Israel. He holds an MBA from Tel Aviv University in financial management, a BA in accounting and Economics from Bar-Ilan University, and is a certified public accountant in Israel.

X

Mr. Vilnai has over 20 years of legal experience in corporate law, commercial law, securities law and international business transactions. Prior to joining PolyPid, Mr. Vilnai served as Associate General Counsel of Ceragon Networks Ltd. (NASDAQ: CRNT). Before Ceragon, he served as Legal Counsel of Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT) and prior to Gilat, as General Counsel and Corporate Secretary of Runcom Technologies Ltd. Mr. Vilnai holds an LLB law degree from the Faculty of Law at the Tel Aviv University. He is licensed to practice law and is a member of the Israeli Bar.

X

Ms. Rubin has over 17 years of leadership experience in the pharmaceutical and biotech industries, specializing in Operations and Quality. Prior to her current role Ms. Rubin served as Vice President of Quality Affairs at PolyPid.

Before joining PolyPid, Ms. Rubin spent 10 years at Teva Pharmaceuticals, where she held Quality Control Director position and other Quality managerial positions.
Ms. Rubin holds a B.Sc. in Drug Chemistry from Bar-Ilan University and an MBA from the Open University in Israel.

X

Ms. Lev-Ari has over 20 years of experience in the HR field. She has vast knowledge in all aspects of HR, with extensive expertise in the pharmaceutical and bio-tech industry. She has held senior positions in HR management, including building HR departments, strategic planning, recruitment, training, talent management, compensation, and benefits. Prior to joining PolyPid Ms. Lev-Ari held various positions as HR Manager at Teva Pharmaceuticals and Insight Pharmaceuticals. She holds a B.A. degree in Behavioral Science and an M.B.A., both from the College of Management Academic Studies (COLMAN).

X

Dr. Nurit Tweezer-Zaks is a senior biopharmaceutical executive with over 20 years of leadership across global pharma, venture capital, and biotech. She spent more than a decade at Sanofi, where she held senior international roles including Global Medical Lead for Established Products and Senior Director of External Innovation, advancing global licensing, partnerships, and lifecycle management.

She later joined aMoon Venture Capital as Operating Partner and Chief Medical Officer, leading global innovation scouting, investment due diligence, and strategic support for portfolio companies. As CEO and CMO of MediCane Health, she advanced preclinical and clinical programs while driving corporate growth and partnerships.

Dr. Tweezer-Zaks began her career as an internist and rheumatologist following a fellowship at the U.S. National Institutes of Health (NIAMS). She earned her MD summa cum laude from Ben Gurion University and an MBA from the Kellogg-Recanati program of Northwestern and Tel Aviv Universities.Chief Medical Officer